What is ADMA Biologics's treasury stock, value, acquired?

ADMA Biologics (ADMA) reported treasury stock, value, acquired of $130.88M in Q1 2026.

What does treasury stock, value, acquired mean?

Represents the total cash outflow used by the company to repurchase its own common shares from the open market. This activity reflects management's capital allocation strategy, often used to return value to shareholders or offset dilution from equity-based compensation plans.

ADMA Biologics ADMA Treasury stock, value, acquired

Treasury stock, value, acquired at other companies

Charles River LaboratoriesCRL

$208.29M-41.0%

Bio-Rad LaboratoriesBIO

——

Other financials

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

See full

Market cap$2.01B-54.5%

Enterprise value$2.08B-52.5%

P/E12.2×-9.2×

P/S4×-5.7×

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockValueAcquiredCostMethod.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's treasury stock, value, acquired.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ADMA Biologics's treasury stock, value, acquired?: ADMA Biologics (ADMA) reported treasury stock, value, acquired of $130.88M in Q1 2026.
What does treasury stock, value, acquired mean?: Represents the total cash outflow used by the company to repurchase its own common shares from the open market. This activity reflects management's capital allocation strategy, often used to return value to shareholders or offset dilution from equity-based compensation plans.